TrialInvestigational new drugs2012

Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.

Myoung Joo Kang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.